Metastatic hormone receptor (HR)-positive, HER2-positive breast cancer represents a biologically distinct subtype comprising approximately 50-60% of all HER2-positive metastatic breast cancers, characterized by dual pathway activation and generally favorable prognosis compared to other HER2-positive subtypes.
Patients with HR-positive/HER2-positive metastatic disease typically present with more favorable tumor biology compared to HR-negative/HER2-positive disease, including lower histological grade, smaller tumor size, and lower rates of nodal involvement.
This subtype demonstrates unique metastatic patterns and exhibits crosstalk between HER2 and estrogen receptor signaling pathways, which can promote resistance when only one pathway is targeted.
The prognosis for HR-positive/HER2-positive metastatic breast cancer is notably better than other subtypes.
Median overall survival ranges from 34-53 months, representing the longest survival among all metastatic breast cancer subtypes.
In comparison, HR-negative/HER2-positive disease has a median overall survival of approximately 40-43 months, while triple-negative disease has the worst prognosis at 8-9 months.
The NCCN guidelines recommend pertuzumab plus trastuzumab plus a taxane (docetaxel or paclitaxel) as preferred first-line therapy.
This dual HER2 blockade combined with chemotherapy represents the standard of care regardless of HR status.
After completing approximately 4-6 cycles of taxane-based induction therapy, patients typically transition to maintenance therapy with trastuzumab plus pertuzumab, with the addition of endocrine therapy for those with HR-positive disease.
An alternative is trastuzumab deruxtecan plus pertuzumab, which showed superior progression-free survival compared to standard trastuzumab-pertuzumab-taxane therapy in the DESTINY-Breast09 trial, with benefits consistent across HR-positive and HR-negative subgroups.
Trastuzumab deruxtecan may be considered in first-line for select patients with rapid progression within 6 months of neoadjuvant/adjuvant therapy (12 months for pertuzumab-containing regimens).
For patients with low disease burden or those unable to tolerate chemotherapy, endocrine therapy plus HER2-targeted therapy is a reasonable option.
Studies have shown that aromatase inhibitors or fulvestrant combined with trastuzumab and/or lapatinib can provide clinical benefit with lower toxicity.
After first-line progression, the NCCN recommends fam-trastuzumab deruxtecan-nxki (T-DXd) as preferred second-line therapy.
Third-line options include tucatinib plus trastuzumab plus capecitabine (particularly for CNS metastases) or ado-trastuzumab emtansine (T-DM1).
For HR-positive disease specifically, endocrine therapy can be continued with HER2-targeted agents throughout multiple lines if patients remain endocrine-sensitive.
The optimal duration of HER2-targeted therapy in patients with long-term disease control remains unknown, and most patients are candidates for multiple sequential lines of therapy.